
Thursday, December 10, 2026 | 14:00 GMT | 15:00 CET | 09:00 EST | 06:00 PST
In difficult-to-treat Gram-negative infections, the value of antimicrobial susceptibility testing (AST) lies not only in how quickly a result is generated, but in whether that result is reliable, clinically meaningful, and available in time to inform treatment decisions.
As antimicrobial resistance (AMR) continues to limit treatment options, laboratories and clinicians increasingly need to balance analytical performance, interpretability, clinical validity, and turnaround time. Faster AST alone is not necessarily better AST. The challenge is ensuring susceptibility information can be trusted, appropriately interpreted, and translated into timely clinical action.
So, how can better and faster susceptibility information support more informed treatment decisions, particularly when managing resistant infections and considering newer or last-resort antibiotics?
Bringing together expertise in clinical microbiology, AST evaluation, infectious and tropical diseases, and molecular microbiology, this SelectScience® webinar will explore the evolving role of susceptibility testing in the AMR era, from generating reliable results to ensuring they reach the right people and inform the right clinical decisions.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.®
Webinar details
- Format: Webinar plus extended Q&A discussion session
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.
Who should attend?
This event is perfect for:
- Clinical microbiologists and laboratory managers
- Clinicians and antimicrobial stewardship teams
- Hospital administrators and healthcare leaders
- Researchers and diagnostic technology developers
What will this webinar cover?
- How increasing AMR is changing clinical decision-making in difficult-to-treat Gram-negative infections and the role of AST in supporting treatment selection.
- The balance between analytical reliability, clinical interpretability, and turnaround time when delivering clinically actionable susceptibility results.
- How newer and last-resort antibiotics, including cefiderocol, illustrate the growing importance of robust and appropriately interpreted susceptibility testing.
- Opportunities to strengthen communication and collaboration between microbiology laboratories and clinicians so that susceptibility information can translate into timely clinical action.
Join the webinar to get answers to these questions:
- How is rising AMR changing treatment decisions in difficult-to-treat Gram-negative infections?
- What makes a susceptibility result reliable, interpretable, and clinically actionable?
- How should laboratories and clinicians balance analytical performance with the need for faster turnaround times?
- How can timely susceptibility information support better-informed antimicrobial treatment decisions?
- What can antibiotics such as cefiderocol tell us about the growing importance of robust and appropriately interpreted AST?
- What communication, workflow, and implementation gaps need to be addressed to translate susceptibility results into clinical action?
Presenters
Dr. Muhammad Alì Muslimani
Physician and Researcher,
University of Pavia and the Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia
Christer Malmberg, PhD
Chief Scientific Officer,
Gradientech
Prof. Dr. Holger Rohde
Senior Physician and Deputy Director of the Institute of Medical Microbiology,
Virology and Hygiene University Medical Center Hamburg-Eppendorf (UKE)